Recent advances in systemic cytotoxic and molecularly targeted therapies coupled with
technologic strides in radiotherapy have the potential to improve outcomes for patients with …

In recent years there has been undoubted progress in the evaluation and development of
targeted agents for non-small cell lung cancer (NSCLC). A major contributor has been the …

Osimertinib (AZD9291) is a third generation epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor that has demonstrated significant clinical benefits in patients with …

Abstract Learning Objectives: After completing this course, the reader will be able to:
Describe the current status of phase II trials with novel agents in order to distinguish the role …

Lung cancer is the most common form of the disease and the leading cause of cancer
deaths worldwide. Non-small-cell lung cancer (NSCLC) accounts for approximately 80-85 …

How and when to use genetic markers for nonsmall cell lung c... : Current Opinion in Pulmonary
Medicine How and when to use genetic markers for nonsmall cell lung cancer : Current Opinion …

The combination of radiotherapy and targeted therapy is an important approach in the
application of targeted therapy in clinical practice, and represents an important opportunity …

Stage III nonsmall cell lung cancer (NSCLC) encompasses a heterogeneous group of
patients, some of whom may be candidates for potentially curative surgery, although for the …

Aims. To establish feasibility of the combination of Erlotinib and concurrent chemoradiation
in pre‐treated patients with locally advanced or metastatic NSCLC. Materials and Methods …

肺癌是全球最常见的恶性肿瘤之一， 严重威胁人类生命。 近年来， 以表皮生长因子受体酪氨酸
激酶抑制剂（ epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs） …